WO2010031832A3 - Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative - Google Patents

Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative Download PDF

Info

Publication number
WO2010031832A3
WO2010031832A3 PCT/EP2009/062101 EP2009062101W WO2010031832A3 WO 2010031832 A3 WO2010031832 A3 WO 2010031832A3 EP 2009062101 W EP2009062101 W EP 2009062101W WO 2010031832 A3 WO2010031832 A3 WO 2010031832A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
thiophene
carboxylic acid
acid derivative
synergistic combinations
Prior art date
Application number
PCT/EP2009/062101
Other languages
French (fr)
Other versions
WO2010031832A2 (en
WO2010031832A9 (en
Inventor
Tse-I Lin
Oliver Lenz
Original Assignee
Ortho-Mcneil-Janssen Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil-Janssen Pharmaceuticals, Inc filed Critical Ortho-Mcneil-Janssen Pharmaceuticals, Inc
Publication of WO2010031832A2 publication Critical patent/WO2010031832A2/en
Publication of WO2010031832A3 publication Critical patent/WO2010031832A3/en
Publication of WO2010031832A9 publication Critical patent/WO2010031832A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to a synergistic combination of the compound of formula (I) or a pharmaceutically acceptable salt thereof, and the compound of formula (II) or a pharmaceutically acceptable salt thereof.
PCT/EP2009/062101 2008-09-18 2009-09-18 Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative WO2010031832A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08164613 2008-09-18
EP08164613.5 2008-09-18

Publications (3)

Publication Number Publication Date
WO2010031832A2 WO2010031832A2 (en) 2010-03-25
WO2010031832A3 true WO2010031832A3 (en) 2010-06-10
WO2010031832A9 WO2010031832A9 (en) 2011-04-14

Family

ID=40085408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/062101 WO2010031832A2 (en) 2008-09-18 2009-09-18 Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative

Country Status (1)

Country Link
WO (1) WO2010031832A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
EA201490836A1 (en) 2011-10-21 2014-11-28 Эббви Инк. COMBINATION TREATMENT (FOR EXAMPLE, WITH ABT-072 OR ABT-333) WITH THE HELP OF DAA FOR USE WHEN TREATING HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
MX360452B (en) 2012-10-19 2018-11-01 Bristol Myers Squibb Co Hepatitis c virus inhibitors.
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (en) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2007014926A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
WO2007092645A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Novel hcv inhibitor combinations and methods
WO2007092616A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
WO2007014926A1 (en) * 2005-07-29 2007-02-08 Tibotec Pharmaceuticals Ltd. Macrocyclic inhibitors of hepatitis c virus
WO2007092645A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Novel hcv inhibitor combinations and methods
WO2007092616A2 (en) * 2006-02-09 2007-08-16 Schering Corporation Combinations comprising hcv protease inhibitor(s) and hcv polymerase inhibitor(s), and methods of treatment related thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SEIWERT ET AL: "[439] ADDITIVE TO SYNERGISTIC ANTIVIRAL EFFECTS OF AN NS3/4A PROTEASE INHIBITOR (ITMN-191) AND AN NS5B RNA-DEPENDENT RNA POLYMERASE INHIBITOR (R1479) IN AN HCV REPLICON SYSTEM", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 46, 1 April 2007 (2007-04-01), pages S167, XP022087779, ISSN: 0168-8278 *
WYLES D L; KAIHARA K A; SCHOOLEY R T: "Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 52, no. 5, May 2008 (2008-05-01), pages 1862 - 1864, XP002507456, ISSN: 0066-4804 *

Also Published As

Publication number Publication date
WO2010031832A2 (en) 2010-03-25
WO2010031832A9 (en) 2011-04-14

Similar Documents

Publication Publication Date Title
WO2010031832A3 (en) Synergistic combinations of a macrocyclic inhibitor of hcv and a thiophene-2-carboxylic acid derivative
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2010105179A3 (en) Inhibitors of beta-secretase
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2007135527A3 (en) Benzimidazolyl compounds
MY148703A (en) Polycyclic cinnamide derivatives
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
TW200612958A (en) Substituted imidazole derivatives
WO2009156462A3 (en) Organic compounds
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
AU2007306104A1 (en) Hydrobenzamide derivatives as inhibitors of Hsp90
WO2007017728A3 (en) Novel heterocyclic compounds
WO2008155615A3 (en) An improved process for the preparation of cephalosporin antibiotic
WO2008048589A3 (en) Compounds and methods for treatment of hcv
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2007112913A3 (en) Benzimidazole derivatives
WO2011011420A3 (en) 3, 4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2008021975A3 (en) Therapeutic lactams
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09783160

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09783160

Country of ref document: EP

Kind code of ref document: A2